1. Targeted inhibition of the immunoproteasome blocks endothelial MHC class II antigen presentation to CD4
- Author
-
Yuwei, Zhang, Xue, Yang, Tao, Bi, Xia, Wu, Lu, Wang, Yafeng, Ren, Yangying, Ou, Chengliang, Xie, Kuangjie, Li, Haolong, Ran, Jing, Wang, Fulan, Zhao, Pixian, Shui, and Jie, Qing
- Subjects
CD4-Positive T-Lymphocytes ,Inflammation ,Liver Cirrhosis ,Antigen Presentation ,Non-alcoholic Fatty Liver Disease ,T-Lymphocytes ,Histocompatibility Antigens Class II ,Endothelial Cells ,Graft vs Host Disease ,Humans - Abstract
Chronic or overwhelming liver injury is frequently associated with fibrosis, which is the main histological characteristic of non-alcoholic steatohepatitis (NASH). Currently, there is no effective treatment for liver fibrosis. Adaptive immunity is one of the perpetrators of liver inflammation and involves the antigen-specific activation of lymphocytes. Targeting adaptive immunity has been proposed as a novel therapeutic approach for NASH. In this study, we demonstrated that liver endothelial cells contribute to MHC class II (MHC-II) antigen presentation to CD4
- Published
- 2021